OnCore Login

Return to Trial Database

HCRN-GI19-405

A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

Status

Study Completed

Cancer Type(s)

Liver and Bile Duct

Study Contact

Publications

A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC)
  • AR He, AY Kim, BM Toskich, K Mody, K Kim, S Stein, L Goyal, TA Abrams, D Brown, LW Goff, RD Kim, N Parikh, T Sandow, D Johnson, RV Iyer, M Petroziello, SS Krishnamurthi, C Martin, Y Jiang, N Akhter

Trial Locations

All sites in which the trial HCRN-GI19-405 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278